As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Vertex have increased 35.78% over the past quarter, and have gained 80.42% in the last ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Federal Territory of Kuala Lumpur, Malaysia - November 5, 2024 — SurgeGraph, one of the leading AI writing tools, today ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with ...

Fintel reports that on November 4, 2024, Jefferies upgraded their outlook for Vertex (NasdaqGM:VERX) from Hold to Buy.

Vertex will host a conference call at 8:30 a.m. Eastern Time today, November 6, 2024, to discuss its third quarter 2024 financial results.

This company selected Vertex in part due to Systax as they have extensive operations in Brazil. In addition, we had a strong ...

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...